Zimmer Biomet Holdings, Inc.
$88.6M 33,496 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Celgene Corporation
Celgene Corporation reported $88,892,365.92 across General Payments, Research, and Ownership to 60,850 physicians and teaching hospitals across 62,972 transactions.
- $88.9M Top 10% payer
- All-tracks total
- 62,972 Top 10% volume
- Transactions
- 60,850 Top 10% reach
- Recipients
- +$1.4M
- General Payments vs PY2023
Celgene Corporation reported $88,892,365.92 across all CMS Open Payments tracks (General + Research + Ownership) to 60,850 physicians and teaching hospitals in Program Year 2024 - ranking #31 of 1,925 reporting manufacturers (0.6% of the all-tracks industry total); General Payments alone were $10,659,425.64, averaging $1.5K per recipient.
How Celgene Corporation's $88.9M all-tracks total breaks down
Celgene Corporation's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
A
98/100
Total payments
A
100/100
Transaction volume
A
100/100
Physician reach
A
100/100
Payment type diversity
A
90/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer celgene-corporation Celgene Corporation
$88.9M · #31/1,925 · 0.6% industry · PY2024
- TOT $88.9M
- RANK #31
- SHARE 0.6%
- TXN 62,972
- RCP 60,850
- CAT 7
- GEN $10.7M
- ΔGEN +$1.4M
- TOP1 72.4%
- PY 2024
Volume peers
Nearest volume peer: Zimmer Biomet Holdings, Inc. ($88.6M)
Celgene Corporation sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Celgene Corporation's CMS-reported General Payments increased by $1.4M (+15.7%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: CELGENE CORPORATIONPY2023: CELGENE CORPORATIONPY2024: Celgene Corporation. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $9,210,209.31
- PY2024
- $10,659,425.64
What the Data Shows for Celgene Corporation
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For Celgene Corporation, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
Of the 7 general-payment categories charted below, "Royalty or License" is the largest at $7.7M across 8 transactions, 72.5% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
"Royalty or License" leads Celgene Corporation's 7-category general-payment breakdown at $7.7M, 72.5% of the reported total.
Celgene Corporation reports 7 general-payment categories - the top three are Royalty or License (72.5%), Food and Beverage (11.8%), and Compensation for Services Other Than Consulting (5.9%). The remaining 4 categories make up 9.7% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Celgene Corporation divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Royalty or License | $7.7M | 8 | 72.5% |
| Food and Beverage | $1.3M | 59,812 | 11.8% |
| Compensation for Services Other Than Consulting | $632.0K | 21 | 5.9% |
| Travel and Lodging | $464.5K | 546 | 4.4% |
| Consulting Fee | $405.1K | 396 | 3.8% |
| Grant | $128.0K | 29 | 1.2% |
| Compensation for Faculty or Speaker (Medical Education) | $41.5K | 38 | 0.4% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $8,300,229.64 (77.9%) of $10,659,425.64 in this company's General Payments records across 17,126 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Celgene Corporation
The five named recipients with the highest reported General Payments from this company
- 1
Seattle Childrens Hospital
$7,718,018.00 across 5 reported transactions
- 2
Dana-Farber Cancer Institute
$314,119.50 across 3 reported transactions
- 3
University Of Kansas Hospital
$103,933.00 across 13 reported transactions
- 4
Langley Porter Psychiatric Hospital
$89,159.14 across 1 reported transactions
- 5
Hospital Of The Univ Of Penna
$75,000.00 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Celgene Corporation ranks #31 of 1,925 by total payments (top 2% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #323 of 1,838 by HHI (top 18% most concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Partner Therapeutics, Inc. : $378.4K total payments, HHI 5272
- Gyrus ACMI, Inc. : $304.0K total payments, HHI 5269
- Boehringer Ingelheim Espana S.A. : $1.6K total payments, HHI 5266
- BioPoly LLC : $35.8K total payments, HHI 5258
- Vascular Graft Solutions Inc : $230.03 total payments, HHI 5258
- Nipro Medical Corporation : $8.2K total payments, HHI 5256
- Celgene Corporation (this company) : $10.7M total payments, HHI 5254
- Suture Ease, Inc. : $12.9K total payments, HHI 5248
- Dr.Reddy's Laboratories,Inc. : $406.3K total payments, HHI 5228
- Vifor Fresenius Medical Care Renal Pharma Ltd. : $5.0K total payments, HHI 5225
- Roche Sequencing Solutions, Inc. : $14.3K total payments, HHI 5222
- Northgate Technologies, Inc. : $21.4K total payments, HHI 5218
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Celgene Corporation's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Celgene Corporation.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Celgene Corporation.
Showing 6 of 1,924 companies with CMS-reported payment data.
CSL Behring
$88.2M 27,644 recipients
Compare payment profiles
Abbott Laboratories
$91.7M 292,558 recipients
Compare payment profiles
Edwards Lifesciences Corporation
$93.0M 70,149 recipients
Compare payment profiles
Incyte Corporation
$84.4M 77,737 recipients
Compare payment profiles
Servier BioInnovation
$83.4M 11 recipients
Compare payment profiles
Put this to use
Celgene Corporation ranks #31 of 1,925 by all-tracks total payments, led by "Royalty or License".
- See where Celgene Corporation sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Royalty or License" spend across every manufacturer, not just Celgene Corporation. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.